Jose Baselga

Summary

Affiliation: Hospital Vall d'Hebron
Country: Spain

Publications

  1. ncbi Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
    J Baselga
    Vall d Hebron University Hospital, Barcelona, Spain
    J Clin Oncol 20:4292-302. 2002
  2. ncbi Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials
    J Baselga
    Medical Oncology Service, Hospital General, Universitari Vall d Hebron, Barcelona, Spain
    Oncology 61:14-21. 2001
  3. ncbi Phase I and II clinical trials of trastuzumab
    J Baselga
    Medical Oncology Service, Hospital General Universitari Vall d Hebron, Barcelona, Spain
    Ann Oncol 12:S49-55. 2001
  4. ncbi Weekly docetaxel in breast cancer: applying clinical data to patient therapy
    J Baselga
    Vall d Hebron University Hospital, Barcelona, Spain
    Oncologist 6:26-9. 2001
  5. ncbi Clinical trials of Herceptin(trastuzumab)
    J Baselga
    Department of Medical Oncology, Hospital General Universitari Vall d Hebron, Psg Vall d Hebron, 119 129, E 08035 Barcelona, Spain
    Eur J Cancer 37:S18-24. 2001
  6. ncbi Targeting epidermal growth factor receptor in lung cancer
    Jose Baselga
    Medical Oncology Service, Hospital General Universitari Vall d Hebron, Paseo Vall d Hebron 119 129, 08035 Barcelona, Spain
    Curr Oncol Rep 4:317-24. 2002
  7. ncbi Focus on breast cancer
    Jose Baselga
    Vall d Hebron University Hospital and Universidad Autonoma de Barcelona, Spain
    Cancer Cell 1:319-22. 2002
  8. ncbi Type I receptor tyrosine kinases as targets for therapy in breast cancer
    J Baselga
    Hospital General Universitari Vall d Hebron, Barcelona, Spain
    J Mammary Gland Biol Neoplasia 2:165-74. 1997
  9. ncbi Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
    J Baselga
    Department of Medicine, Breast Cancer Medicine and Genitourinary Medicine Services, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 18:904-14. 2000
  10. ncbi Why the epidermal growth factor receptor? The rationale for cancer therapy
    Jose Baselga
    Medical Oncology Service, Hospital General Universitari Vall d Hebron, Barcelona, Spain
    Oncologist 7:2-8. 2002

Collaborators

Detail Information

Publications109 found, 100 shown here

  1. ncbi Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
    J Baselga
    Vall d Hebron University Hospital, Barcelona, Spain
    J Clin Oncol 20:4292-302. 2002
    ....
  2. ncbi Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials
    J Baselga
    Medical Oncology Service, Hospital General, Universitari Vall d Hebron, Barcelona, Spain
    Oncology 61:14-21. 2001
    ..Numerous studies are underway or planned to evaluate other Herceptin combinations and regimens in the metastatic and adjuvant settings...
  3. ncbi Phase I and II clinical trials of trastuzumab
    J Baselga
    Medical Oncology Service, Hospital General Universitari Vall d Hebron, Barcelona, Spain
    Ann Oncol 12:S49-55. 2001
    ..The pharmacokinetics of trastuzumab were evaluated in these studies and the results are summarized...
  4. ncbi Weekly docetaxel in breast cancer: applying clinical data to patient therapy
    J Baselga
    Vall d Hebron University Hospital, Barcelona, Spain
    Oncologist 6:26-9. 2001
    ..It may also be a helpful means of delivering a highly active cytotoxic drug in combination with radiation therapy, other proven chemotherapy agents such as doxorubicin, and new, highly promising biological agents such as HERCEPTIN:..
  5. ncbi Clinical trials of Herceptin(trastuzumab)
    J Baselga
    Department of Medical Oncology, Hospital General Universitari Vall d Hebron, Psg Vall d Hebron, 119 129, E 08035 Barcelona, Spain
    Eur J Cancer 37:S18-24. 2001
    ..1 months following administration of single-agent trastuzumab. Notably, 2% of patients were free of disease progression at 6 months. The safety profile of trastuzumab either given alone or in combination was favourable...
  6. ncbi Targeting epidermal growth factor receptor in lung cancer
    Jose Baselga
    Medical Oncology Service, Hospital General Universitari Vall d Hebron, Paseo Vall d Hebron 119 129, 08035 Barcelona, Spain
    Curr Oncol Rep 4:317-24. 2002
    ..These exciting results and plans are further complemented by an emerging number of compounds in clinical development, including both monoclonal antibodies (ie, IMC-C225) and other tyrosine kinase inhibitors, directed at the EGFR...
  7. ncbi Focus on breast cancer
    Jose Baselga
    Vall d Hebron University Hospital and Universidad Autonoma de Barcelona, Spain
    Cancer Cell 1:319-22. 2002
  8. ncbi Type I receptor tyrosine kinases as targets for therapy in breast cancer
    J Baselga
    Hospital General Universitari Vall d Hebron, Barcelona, Spain
    J Mammary Gland Biol Neoplasia 2:165-74. 1997
    ..In addition, compounds that inhibit receptor tyrosine kinases have shown significant preclinical activity and are potential candidates for clinical testing...
  9. ncbi Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
    J Baselga
    Department of Medicine, Breast Cancer Medicine and Genitourinary Medicine Services, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 18:904-14. 2000
    ..We evaluated the pharmacokinetics and toxicity of C225 in patients with advanced tumors overexpressing EGF receptors...
  10. ncbi Why the epidermal growth factor receptor? The rationale for cancer therapy
    Jose Baselga
    Medical Oncology Service, Hospital General Universitari Vall d Hebron, Barcelona, Spain
    Oncologist 7:2-8. 2002
    ..Thus, the rationale for EGFR-targeted approaches to cancer treatment is apparent and now well established, and there is increasing evidence that they may represent a significant contribution to cancer therapy...
  11. ncbi HER-targeted tyrosine-kinase inhibitors
    Jose Baselga
    Medical Oncology Service, Hospital General, Universitari Vall d Hebron, Pg Vall d Hebron 199 129, E 08035 Barcelona, Spain
    Oncology 63:6-16. 2002
    ..Early data show that they are generally well tolerated and have provided evidence of antitumor activity. HER-TK inhibitors are exciting agents that are likely to have a substantial impact on the way we treat patients with cancer...
  12. ncbi Epithelial growth factor receptor interacting agents
    Jose Baselga
    Medical Oncology Service, Hospital General Universitari Vall d Hebron, Paseo Vall d Hebron 119 129, 08035 Barcelona, Spain
    Hematol Oncol Clin North Am 16:1041-63. 2002
    ..The results of ongoing studies with these agents in diverse indications and tumor types may establish the role of these promising therapies to our current cancer treatments...
  13. ncbi Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
    J Baselga
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 58:2825-31. 1998
    ..Clinical trials that are built on these results are under way...
  14. ncbi The EGFR as a target for anticancer therapy--focus on cetuximab
    J Baselga
    Medical Oncology Service, Hospital General Universitari Vall d Hevron, Paseo Vall d Hebron 119 129, 08035, Barcelona, Spain
    Eur J Cancer 37:S16-22. 2001
    ..Based on these promising results, additional phase II and phase III trials are currently underway in head and neck and colorectal cancer...
  15. doi A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers
    Josep Lluís Parra-Palau
    Statistics Department, Faculty of Biology, Vall d Hebron Institute of Oncology, University of Barcelona, Barcelona, Spain
    Cancer Res 70:8537-46. 2010
    ..2%). These results reveal a mechanism of ER regulation mediated by HER2, which suggests a new strategy to improve responses to endocrine therapy in breast cancer...
  16. ncbi Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting
    Pablo Matar
    Laboratory of Oncology Research, Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 10:6487-501. 2004
    ....
  17. pmc RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
    Violeta Serra
    Experimental Therapeutics, Vall d Hebron Institute of Oncology, Barcelona, Spain
    J Clin Invest 123:2551-63. 2013
    ..These observations provide a strong rationale for the combined use of RSK and PI3K pathway inhibitors to elicit favorable responses in breast cancer patients with activated RSK...
  18. pmc Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor
    Maurizio Scaltriti
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 16:2688-95. 2010
    ..We have studied the correlation between p95HER2 expression and response to lapatinib, both in preclinical models and in the clinical setting...
  19. doi NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
    Violeta Serra
    Laboratory of Oncology Research, Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer Res 68:8022-30. 2008
    ..In summary, NVP-BEZ235 inhibits the PI3K/mTOR axis and results in antiproliferative and antitumoral activity in cancer cells with both wild-type and mutated p110-alpha...
  20. doi Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy
    Celina García-García
    Department of Experimental Therapeutics Laboratory, Vall d Hebron Institute of Oncology, Pg Vall d Hebron, Barcelona, Spain
    Clin Cancer Res 18:2603-12. 2012
    ..The hypothesis is that the suppression of this pathway results in sensitization to anti-HER2 agents. However, this combinatorial strategy has not been comprehensively tested in models of trastuzumab and lapatinib resistance...
  21. ncbi Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer
    Jose Baselga
    Medical Oncology Service, Vall d Hebron University Hospital, P Vall d Hebron 119 129 08035 Barcelona, Spain
    J Clin Oncol 23:5323-33. 2005
    ..To evaluate the antitumor activity and pharmacodynamic/biologic effect of gefitinib 500 mg/day monotherapy in patients with previously treated, advanced breast cancer...
  22. doi USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma
    Pieter J A Eichhorn
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Nat Med 18:429-35. 2012
    ..Our results show that USP15 regulates the TGF-β pathway and is a key factor in glioblastoma pathogenesis...
  23. ncbi ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells
    Judit Anido
    Laboratory of Oncology Research, Medical Oncology Service, Vall d Hebron University Hospital, Barcelona 08035, Spain
    Clin Cancer Res 9:1274-83. 2003
    ..Our aim was to explore the effects of ZD1839 in breast cancer cell lines expressing different levels of EGFR and the closely related HER2 receptor...
  24. ncbi Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and n
    Jose Baselga
    Vall d Hebron University Hospital, Oncology Service, P Vall d Hebron 119 129, Barcelona 08035, Spain
    J Clin Oncol 23:5568-77. 2005
    ....
  25. doi Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study
    Javier Cortes
    Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 15:307-14. 2009
    ....
  26. ncbi 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis
    Federico Rojo
    Department of Pathology, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 13:81-9. 2007
    ....
  27. doi Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer
    Jose Baselga
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Clin Oncol 31:2586-92. 2013
    ..Epidermal growth factor receptor is overexpressed in metastatic triple-negative breast cancers (mTNBCs), an aggressive subtype of breast cancer. Our randomized phase II study investigated cisplatin with or without cetuximab in this setting...
  28. pmc Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer
    Matthew J Ellis
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63119, USA
    Breast Cancer Res Treat 119:379-90. 2010
    ..Nonetheless, as with other recent studies, a favorable interaction between PIK3CA KD mutation and prognosis was detected. The mechanism for the favorable prognostic impact of PIK3CA mutation status therefore remains unexplained...
  29. doi Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer
    Jose Baselga
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron, Barcelona, Spain
    J Clin Oncol 27:2630-7. 2009
    ..This study explored whether sensitivity to letrozole was enhanced with the oral mTOR inhibitor, everolimus (RAD001)...
  30. ncbi Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma
    Federico Rojo
    Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    J Clin Oncol 24:4309-16. 2006
    ..The objective of this study was to assess the in situ biologic activity of the EGFR tyrosine kinase inhibitor gefitinib in gastric tumor samples in a phase II study...
  31. doi Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer
    Jose Baselga
    Vall d Hebron University Hospital, Barcelona, Spain
    J Clin Oncol 27:526-34. 2009
    ..Gene expression studies were undertaken using genes that were identified as potentially associated with sensitivity/resistance to ixabepilone in prior preclinical investigations...
  32. pmc Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients
    Maurizio Scaltriti
    Departments of Medical Oncology and Molecular Pathology, Vall d Hebron Institute of Oncology, 08035 Barcelona, Spain
    Proc Natl Acad Sci U S A 108:3761-6. 2011
    ....
  33. doi Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron, 119 129, 08035 Barcelona, Spain
    J Clin Oncol 28:1181-9. 2010
    ....
  34. pmc mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling
    Vanessa S Rodrik-Outmezguine
    Program in Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Discov 1:248-59. 2011
    ..These findings reveal the adaptive capabilities of oncogenic signaling networks and the limitations of monotherapy for inhibiting feedback-regulated pathways...
  35. pmc AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
    Sarat Chandarlapaty
    Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Cell 19:58-71. 2011
    ..Consistent with this model, we find that, in tumors in which AKT suppresses HER3 expression, combined inhibition of AKT and HER kinase activity is more effective than either alone...
  36. ncbi Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors
    Emiliano Calvo
    Vall d Hebron University Hospital, Universidad Autonoma de Barcelona, Barcelona, Spain
    J Clin Oncol 24:2158-63. 2006
    ..Therefore, in clinical trials with tyrosine kinase inhibitors and other molecular-targeted therapies, the inclusion of a global population appears to be required...
  37. pmc HER2 carboxyl-terminal fragments regulate cell migration and cortactin phosphorylation
    Jesús García-Castillo
    Medical Oncology Research Program, Vall d Hebron University Hospital, Passeig Vall d Hebron 119 129, 08035 Barcelona, Spain
    J Biol Chem 284:25302-13. 2009
    ..These results suggest that cortactin is a target of 611-CTF involved in the regulation of cell migration and, thus, in the metastatic behavior of breast tumors expressing this CTF...
  38. pmc A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis
    Kim Pedersen
    Medical Oncology Research Program, Vall d Hebron University Hospital, Psg Vall d Hebron 119 129, 08035 Barcelona, Spain
    Mol Cell Biol 29:3319-31. 2009
    ..These results demonstrate that 611-CTF is a potent oncogene capable of promoting mammary tumor progression and metastasis...
  39. doi Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors
    Jose Baselga
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Spain
    Clin Cancer Res 16:4876-83. 2010
    ..Tumor biopsy samples were taken to investigate the effect of saracatinib on Src activity in tumors...
  40. pmc Proteomic identification of desmoglein 2 and activated leukocyte cell adhesion molecule as substrates of ADAM17 and ADAM10 by difference gel electrophoresis
    Joan J Bech-Serra
    Medical Oncology Research Program, Vall d Hebron University Hospital Research Institute, 08035 Barcelona, Spain
    Mol Cell Biol 26:5086-95. 2006
    ..Since loss of cell adhesion is an early event in tumor development, these results suggest that ADAM17 is a useful target in anticancer therapy...
  41. doi A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors
    Francesco Atzori
    Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Cancer Res 17:6304-12. 2011
    ..This study was designed to evaluate the safety and tolerability of dalotuzumab, determine the pharmacokinetic (PK) and pharmacodynamic (PD) profiles, and identify a recommended phase II dose...
  42. pmc Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation
    Judit Anido
    Medical Oncology Research Program, Vall d Hebron University Hospital Research Institute, Barcelona, Spain
    EMBO J 25:3234-44. 2006
    ..Thus, the kinase domain seems necessary for the activity of HER2 CTFs and the presence of these HER2 fragments could account for the resistance to treatment with antibodies...
  43. doi Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy
    Jose Baselga
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Paseo Vall d Hebron 119 129, Barcelona, Spain E 08035
    J Clin Oncol 28:1138-44. 2010
    ..This phase II trial assessed the efficacy and safety profile of the combination in patients with HER2-positive breast cancer whose disease had progressed during prior trastuzumab-based therapy...
  44. pmc Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235
    Pieter J A Eichhorn
    Medical Oncology Program, Vall d Hebron Institut de Oncologia, Barcelona, Spain
    Cancer Res 68:9221-30. 2008
    ..Our data show that deregulation of the PI3K pathway, either through loss-of-function mutations in PTEN or dominant activating mutations in PIK3CA, leads to lapatinib resistance, which can be effectively reversed by NVP-BEZ235...
  45. doi Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib
    Susana Cedres
    Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Lung Cancer 66:257-61. 2009
    ..Inhibition of the EGFR pathway is a useful strategy in the treatment of patients with advanced NSCLC. The aim of this study is to assess predictive clinical parameters of efficacy...
  46. pmc A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial
    Jose Baselga
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Trials 14:228. 2013
    ..Here we describe RESILIENCE - a multinational, double-blind, randomized, placebo-controlled, phase 3 trial - assessing the addition of sorafenib to first- or second-line capecitabine in advanced HER2-negative breast cancer...
  47. ncbi Future options with trastuzumab for primary systemic and adjuvant therapy
    Jose Baselga
    Vall d Hebron University, Barcelona, Spain
    Semin Oncol 31:51-7. 2004
    ..Together, this extensive program, which includes analysis of predictive molecular and pathologic makers, will establish the efficacy, safety, and role of trastuzumab in early breast cancer...
  48. doi A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy
    Enriqueta Felip
    Medical Oncology Service and Pathology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 14:3867-74. 2008
    ..To examine potential markers of clinical benefit and the effects of erlotinib on the epidermal growth factor receptor (EGFR) signaling pathway in advanced non-small cell lung cancer patients refractory to platinum-based chemotherapy...
  49. doi TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma
    Judit Anido
    Vall d Hebron Institute of Oncology, Barcelona, Spain
    Cancer Cell 18:655-68. 2010
    ..High CD44 and Id1 levels confer poor prognosis in GBM patients...
  50. ncbi Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer
    Josep Castellvi
    Department of Pathology, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer 107:1801-11. 2006
    ....
  51. ncbi Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?
    Carlos L Arteaga
    Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Cancer Cell 5:525-31. 2004
    ....
  52. ncbi Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition
    Joan Albanell
    Oncology Service, Vall d Hebron University Hospital, Paseo Vall d Hebron 119 129, Barcelona 08035, Spain
    J Clin Oncol 20:110-24. 2002
    ..We studied the pharmacodynamic effects of ZD1839 on EGFR in the skin, an EGFR-dependent tissue, in cancer patients participating in ZD1839 phase I clinical trials...
  53. doi PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition
    Yasir H Ibrahim
    Experimental Therapeutics Laboratory, Vall d Hebron Institute of Oncology VHIO, Pg Vall d Hebron, Barcelona, Spain
    Cancer Discov 2:1036-47. 2012
    ....
  54. pmc CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity
    Ron Firestein
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Nature 455:547-51. 2008
    ..Together these observations suggest that therapeutic interventions targeting CDK8 may confer a clinical benefit in beta-catenin-driven malignancies...
  55. doi Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics
    Teresa Macarulla
    Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Mol Cancer Ther 9:2844-52. 2010
    ..Pharmacodynamic analyses in mitotic cells of both skin and tumor provided proof of mechanism for Aurora A kinase inhibition. A more potent, selective, second-generation Aurora A kinase inhibitor, MLN8237, is in clinical development...
  56. doi Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, corrected Barcelona, Spain
    J Clin Oncol 26:1603-10. 2008
    ..In order to identify a rationally based dose and schedule for cancer treatment, we have conducted a tumor pharmacodynamic phase I study in patients with advanced solid tumors...
  57. ncbi 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications
    Gemma Armengol
    Department of Pathology, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer Res 67:7551-5. 2007
    ..Further investigation into this concept may identify additional funnel factors in the oncogenic pathways and provide potential therapeutic targets...
  58. doi Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
    Jose Baselga
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Passeig Vall d Hebron 119 129, Barcelona 08035, Spain
    Nat Rev Cancer 9:463-75. 2009
    ..These new therapies include tyrosine kinase inhibitors, antibody-chemotherapy conjugates, heat-shock protein inhibitors and antibodies that interfere with the formation of ERBB2-ERBB3 dimers...
  59. ncbi Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule
    Jose Baselga
    Vall d Hebron, University Hospital, Department of Medical Oncology, Pg Vall d Hebron, 119 129, E 08035 Barcelona, Spain
    J Clin Oncol 23:2162-71. 2005
    ....
  60. ncbi Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer
    Jose Baselga
    Vall d Hebron University Hospital, Oncology Service, Barcelona, Spain
    Oncologist 11:4-12. 2006
    ..Overall, results from clinical trials are sufficiently compelling to consider 1 year of adjuvant trastuzumab treatment for women with HER-2-positive EBC based on the risk:benefit ratio demonstrated in these studies...
  61. doi Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer
    Maurizio Scaltriti
    Medical Oncology Department, Vall d Hebron Institute of Oncology, Barcelona, Spain
    Mol Cancer Ther 10:817-24. 2011
    ..IPI-504-mediated Hsp90 inhibition may represent a novel therapeutic approach in trastuzumab refractory HER2-positive breast cancer...
  62. ncbi Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy
    Luca Gianni
    Istituto Nazionale Tumori, Milan, Italy, and Hospital Vall d Hebron, Barcelona, Spain
    Clin Cancer Res 11:8715-21. 2005
    ..We report here feasibility, tolerability, locoregional antitumor activity, and breast conservation rate...
  63. ncbi Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
    James A Bonner
    Department of Medicine, University of Alabama, Birmingham, USA
    N Engl J Med 354:567-78. 2006
    ....
  64. ncbi Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments
    J Albanell
    Laboratory of Oncology Research, Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, Spain
    Cancer Res 61:6500-10. 2001
    ..The inhibition of ERK1/2 activation in vitro and in vivo by compounds targeting the EGF receptor points to the interest of ERK1/2 as potential surrogate markers of EGF-receptor signaling in clinical therapeutic studies...
  65. doi Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence
    Pier Davide Angelini
    Preclinical Research, Vall d Hebron Institute of Oncology VHIO, Barcelona, Spain
    Cancer Res 73:450-8. 2013
    ..Underscoring the functional relevance of the p95HER2-induced senescence secretome, we show that p95HER2-induced senescent cells promote metastasis in vivo in a non-cell-autonomous manner...
  66. doi A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors
    Eduardo Vilar
    Department of Medical Oncology, Vall d Hebron University Hospital, Ps Vall d Hebron, 119 129, 08035 Barcelona, Spain
    Invest New Drugs 30:299-305. 2012
    ..A phase I study was performed in patients with advanced solid tumors to determine the maximum tolerated dose (MTD), establish a safety profile, and to evaluate pharmacokinetics and efficacy of the drug...
  67. ncbi High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene
    Alejandra Bruna
    Medical Oncology Program, Vall d Hebron University Hospital Research Institute, 08035 Barcelona, Spain
    Cancer Cell 11:147-60. 2007
    ..The epigenetic regulation of the PDGF-B gene dictates whether TGFbeta acts as an oncogenic factor inducing PDGF-B and proliferation in human glioma...
  68. doi TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma
    Silvia Peñuelas
    Medical Oncology Program, Vall d Hebron University Hospital Research Institute, Barcelona, Spain
    Cancer Cell 15:315-27. 2009
    ..Our results show that TGF-beta and LIF have an essential role in the regulation of GICs in human glioblastoma...
  69. ncbi Critical update and emerging trends in epidermal growth factor receptor targeting in cancer
    Jose Baselga
    Medical Oncology Service, Vall d Hebron Research Institute and Vall d Hebron University Hospital, Paseo Vall d Hebron 119 129, Barcelona 08035, Spain
    J Clin Oncol 23:2445-59. 2005
    ....
  70. doi Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]
    Serena Di Cosimo
    Breast Cancer Center, Medical Oncology Department, Vall d Hebron Institute of Oncology VHIO, Vall d Hebron University Hospital, 08035 Barcelona, Spain
    Nat Rev Clin Oncol 7:139-47. 2010
    ..Thus, the overall management of breast cancer will increasingly require an understanding of breast cancer heterogeneicity, the biological nature of any given tumor as well the existence of increased personalized treatment options...
  71. doi Targeted therapies in breast cancer: where are we now?
    Serena Di Cosimo
    Medical Oncology Program, Medical Oncology Department, Vall d Hebron University Hospital, Passeig Vall d Hebron, Barcelona, Spain
    Eur J Cancer 44:2781-90. 2008
    ..We will present these novel therapies and will analyse for each target the developmental status of some of the agents as well as target-specific challenges...
  72. doi Phosphoinositide 3-kinase mutations in breast cancer: a "good" activating mutation?
    Serena Di Cosimo
    Medical Oncology Department, Vall d Hebron Institute of Oncology VHIO, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Cancer Res 15:5017-9. 2009
    ..These findings will have to be considered in the design and interpretation of clinical trials with inhibitors of the PI3K pathway...
  73. ncbi Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity
    Frederick Y Wu
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Cancer Res 66:2162-72. 2006
    ..These data suggest that cytoplasmic p27 can exert oncogenic functions by modulating Akt stability, cell survival, and tumorigenicity...
  74. doi CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer
    Jose Baselga
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Clin Breast Cancer 10:489-91. 2010
    ..Combining trastuzumab and pertuzumab therefore provides a more comprehensive blockade of the HER signaling pathways, resulting in greater antitumor efficacy...
  75. doi Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
    M Scaltriti
    Medical Oncology Department, Vall d Hebron Research Institute, Vall d Hebron University Hospital, Barcelona, Spain
    Oncogene 28:803-14. 2009
    ..We propose that this is a novel mechanism of action of the combination that may be clinically relevant and exploitable in the therapy of patients with HER2-positive tumors...
  76. doi Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels
    A Prat
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 20:294-7. 2009
    ..In addition, we tested the new proposed early CA-125 signal of progressive disease (EPD) criterion in the same study population...
  77. ncbi A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer
    J Tabernero
    Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 15:1358-65. 2004
    ..A phase II randomised trial was conducted to evaluate the tolerability and activity of weekly or 3-weekly docetaxel in patients with metastatic breast cancer...
  78. pmc Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion
    Adam J Bass
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Nat Genet 43:964-8. 2011
    ..This study shows previously unidentified levels of genomic rearrangements in colorectal carcinoma that can lead to essential gene fusions and other oncogenic events...
  79. doi p95HER2 and breast cancer
    Joaquin Arribas
    Vall d Hebron Institute of Oncology VHIO, Barcelona, Spain
    Cancer Res 71:1515-9. 2011
    ....
  80. ncbi Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine
    Joaquim Bellmunt
    Medical Oncology Sevice, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer 95:751-7. 2002
    ....
  81. ncbi Epidermal growth factor receptor pathway inhibitors
    Jose Baselga
    Medical Oncology Service, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Spain
    Cancer Chemother Biol Response Modif 22:205-23. 2005
  82. ncbi Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma
    Robert J Motzer
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 21:99-101. 2003
    ..The lack of clinical response or suggestion of prolonging time to progression compared to historical data with interferon-alfa supports no further study of single-agent C225 in patients with metastatic RCC...
  83. ncbi Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group
    J Bellmunt
    Hospital General Universitari Vall d Hebron, Bacelona, Spain
    J Clin Oncol 18:3247-55. 2000
    ..To determine the maximum-tolerated dose and the antitumor activity of a combination of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma (TCC) of the urothelium...
  84. ncbi Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy
    J Bellmunt
    Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 18:522-8. 2007
    ..Since DNA damaging agents are the cornerstones of therapy, we hypothesized that levels of DNA repair genes could predict survival...
  85. ncbi Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study
    E Felip
    Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 14:1549-54. 2003
    ..Poor survival rates in extensive-stage small-cell lung cancer (SCLC) patients prompted us to evaluate a sequential dose-dense schedule of paclitaxel followed by topotecan...
  86. ncbi Mechanism of action of trastuzumab and scientific update
    J Baselga
    Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, Spain
    Semin Oncol 28:4-11. 2001
    ..The ability of trastuzumab to inhibit HER2 cleavage may correlate with the clinical anticancer activity of the multifunctional HER2-targeting antibody...
  87. ncbi Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells
    M A Molina
    Laboratory of Oncology Research, Medical Oncology Service, Universitat Autonoma de Barcelona, Vall d Hebron University Hospital, 08035 Barcelona, Spain
    Cancer Res 61:4744-9. 2001
    ..We propose that the inhibition of HER2 cleavage and prevention of the production of an active truncated HER2 fragment represent a novel mechanism of action of trastuzumab...
  88. ncbi Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer
    A Prat
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 19:327-31. 2008
    ..The aim of this retrospective study is to analyze the prognostic value of the CA-125 nadir after the completion of an optimal primary treatment...
  89. ncbi Mechanism of action of anti-HER2 monoclonal antibodies
    J Baselga
    Medical Oncology Service, Hospital General Universitari Vall d Hebron, Barcelona, Spain
    Ann Oncol 12:S35-41. 2001
    ..The significance of these mechanisms for selection of concomitant chemotherapy is also considered...
  90. ncbi New drugs and new approaches in metastatic bladder cancer
    J Bellmunt
    Hospital General Universitari Vall d Hebron, P Vall d Hebron 119 129, 08035 Barcelona, Spain
    Crit Rev Oncol Hematol 47:195-206. 2003
    ....
  91. ncbi Novel agents in the era of targeted therapy: what have we learned and how has our practice changed?
    J Baselga
    Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 19:vii281-8. 2008
  92. ncbi Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer
    J Bellmunt
    Hospital General Universitari Vall d Hebron, P Vall d Hebron 119 129, 08035, Barcelona, Spain
    Eur J Cancer 36:17-25. 2000
    ..The potential clinical benefit of these new three-drug combinations in the treatment of TCC needs to be tested in future phase III studies...
  93. ncbi Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer
    J Bellmunt
    Medical Oncology Service, Hospital General Universitari Vall d Hebron, Passeig Vall d Hebron 119 129, 08035 Barcelona, Spain
    Cancer Invest 20:673-85. 2002
    ..This schedule merits further investigation in a phase-II trial...
  94. ncbi A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer
    J Bellmunt
    University Hospital Vall d Hebron, Barcelona, Spain
    Eur J Cancer 37:2212-5. 2001
    ..Based on these data, a randomised trial in the framework of the EORTC-Genitourinary (GU) group of gemcitabine/carboplatin versus carboplatin/methotrexate/vinblastine (MCAVI) is ongoing...
  95. ncbi New horizons: gene therapy for cancer
    J Baselga
    Hopital General Universtari Vall d Hebron, Servico de Oncologia Medica, Barcelona, Spain
    Anticancer Drugs 10:S39-42. 1999
    ..There is preliminary clinical evidence suggesting that the in vivo synergy seen between Ad5CMV-p53 and cisplatin may also occur in patients. Phase II trials are justified and have been started...
  96. pmc Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
    S Chandarlapaty
    Department of Medicine, Memorial Sloan Kettering Cancer Center MSKCC, New York, NY 10065, USA
    Oncogene 29:325-34. 2010
    ..HSP90 inhibition is therefore a potentially effective therapeutic strategy for p95-HER2-mediated Trastuzumab-resistant breast cancer...
  97. ncbi Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy
    C Hudis
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 17:93-100. 1999
    ..Dose-dense chemotherapy is predicted to be a superior treatment plan. Therefore, we studied dose-dense doxorubicin, paclitaxel, and cyclophosphamide (A-->T-->C) as adjuvant therapy...
  98. ncbi Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer
    A D Seidman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 16:3353-61. 1998
    ..To evaluate the efficacy and toxicity of paclitaxel administered as a 1-hour infusion on weekly basis, without interruption, to patients with metastatic breast cancer who had received prior therapy...
  99. ncbi Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839
    J Albanell
    Medical Oncology Service, Vall d'Hebron Hospital, Barcelona, Spain
    Semin Oncol 28:56-66. 2001
    ..Based on these encouraging results, studies assessing activated EGFR, activated MAPK, and other selected markers in phase II trials in tumors from patients treated with ZD1839 are currently planned or ongoing...
  100. ncbi Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer
    A D Seidman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 14:1877-84. 1996
    ..The tolerability of this strategy and its pharmacokinetic profile and pharmacodynamic correlates were also investigated...
  101. doi Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study
    J Tabernero
    Medical Oncology Service, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Ann Oncol 21:1537-45. 2010
    ....